Citra Anticoagulants, Inc. and H.A.C. Pharma Sign Marketing Agreement For Promotion Of LOXXIT™ Catheter Lock Solution To The EMEA Market

Citra Anticoagulants, Inc. a worldwide distributor of citrate-based anticoagulants reported that it has signed a Marketing Services Agreement with H.A.C. Pharma for LOXXIT™ Catheter Lock Solution.

Braintree, MA (PRWEB) September 20, 2007 - Citra Anticoagulants, Inc. a leading, developer and worldwide distributor of citrate-based anticoagulants used in dialysis, reconstructive, and orthopaedic markets, reported today that is has signed an exclusive Marketing Services Agreement with H.A.C. Pharma for Loxxit™ Catheter Lock Solution.

The Agreement appoints H.A.C. Pharma as Citra's sole representative to promote the marketing and sales activities of LOXXIT™ Catheter Lock Solution, 46.7% Trisodium Citrate Dihydrate, to distributors in Europe, the Middle East, and Africa.

H.A.C. Pharma is headquartered in Caen, France. It is a pharmaceutical marketing company focused on specialty therapeutic areas. The company commercializes drugs, medical devices, and food supplements for medical purposes in France and throughout the world. For more information and how to contact H.A.C. Pharma, visit www.hacpharma.com.

Ronald H. Lewis, Ph.D., President of Citra Anticoagulants, Inc. said, "We are extremely excited about partnering our LOXXIT™ Catheter Lock Solution with H.A.C. Pharma in the EMEA medical arena. LOXXIT™ is an excellent preventive-action product and H.A.C. Pharma has a strong sales/marketing team committed to exceeding customer expectations. The future for the combination of LOXXIT™ with H.A.C. Pharma is extremely bright."

Citra Anticoagulants, Inc. is a privately held company headquartered in the United States, 10 minutes outside of Boston, Massachusetts. Team Citra embraces the mission to develop and market safe and effective citrate-based anticoagulants for the medical community, while providing outstanding customer service. Citra's products are used in many different applications: from the anticoagulant of choice in the preparation of platelet rich plasma, which is used as an aid in wound healing, to the anticoagulant of choice for the collection of granulocytes which are used to support patients undergoing cancer therapy, and to a superb catheter lock solution where the product functions as an anticoagulant and an antimicrobial agent.

Citra's products are manufactured under Current Good Manufacturing Practices (cGMPs). The manufacturing facility is registered with the United States Food & Drug Administration as a Drug and Medical Device Facility and is EN ISO 13485:2003 certified (Reg. No. 44 221 07 345443-001) by TUV NORD.

###